ReZoom™ intraocular lens (IOL), FDA-approved in March 2005

A cataract is a cloudy formation on the crystalline lens which may prevent a clear image from forming on the retina. More than 50 percent of people over age 55 have these lens opacities and over 70 percent of those over age 75 have this condition. Cataracts can impair vision and treatment is necessary. While natural aging is the most frequent cause, others include injury, chronic eye disease, and other diseases such as diabetes.

Watch and listen to Gary Player answer questions about his experience with the ReZoom Procedure.

New Technology

The ReZoom™ IOL is a second-generation refractive multifocal acrylic IOL that provides cataract patients with greater independence from glasses than monofocal IOLs. It features Balanced View Optics™ technology that distributes light over five optic zones for enhanced restoration of visual function, providing distance, intermediate and near vision for reduced spectacle dependence. ReZoom™ lenses are so effective, 92 percent of its patients never or seldom need to wear glasses.

Benefits

For the patient

• the surgical period requires only local anesthesia
• the intraocular lens also corrects the patient's refractive error
• return of visual function is rapid

This allows cataract patients to resume their lives with a full range of vision in varying light. The ReZoom™ intraocular lens is a second-generation refractive multifocal IOL that provides hyperopic cataract patients with greater independence from glasses than monofocal IOLs. The ReZoom™ proprietary multifocal design provides a range of vision that monfocals cannot match.

The ReZoom™ IOL is indicated for the visual correction of aphakia in persons 60 years of age or older in whom a cataractous lens has been removed and who may benefit from useful near vision without reading add and increased spectacle independence across a range of distances. It is intended to be placed in the capsular bag.